Screening for prostatakreft i Norge

Authors

  • Sophie D. Fosså
  • P. Å. Høisæter

DOI:

https://doi.org/10.5324/nje.v11i2.549

Abstract

 

ENGLISH SUMMARY

Fosså SD, Høisæter PÅ.

 

Screening for prostate cancer in Norway. Nor J Epidemiol 2001; 11 (2): 147-152.

Background

 

 

Results

 

 

Conclusion

 

 

. Population-based PSA screening can not be recommended in Norway. PSA-based opportunistic

screening should be substantially reduced. If an asymptomatic man persistently requires PSA

testing, the responsible doctor has to inform him about the potential disadvantages as well as the potential

benefits associated with opportunistic screening, diagnosis and treatment of prostate cancer. PSAscreening

should be considered as a public health care strategy, depending on the results of the ERPCS.

. The rate of opportunistic screening in Norway in elderly men was about 7% in 1999 but is

increasing, with significant differences between the counties. The current health care strategy is to limit

opportunistic screening to a minimum, as the effectiveness of this task is unproven. Reduction of mortality

can only be achieved by the early diagnosis and treatment of “clinically important” prostate

cancer. The identification of these cases remains problematic in clinical routine. Data from the Cancer

Registry of Norway, and knowledge about prostate cancer tumour biology and epidemiology leave

doubt whether the aim of the ERPCS can be reached in 2008: The Norwegian Urological Cancer Group

has therefore not recommended Norway's participation in the ERPCS.

. PSA-based opportunistic screening for prostate cancer is increasing throughout the

world, and also in Norway. The mortality reducing effectiveness of population-based PSA screening

has, however, so far not been proven and it is currently addressed by a European randomised trial

(ERPCS). This trial aims to demonstrate a 20% reduction of the prostate cancer-related mortality rate in

the year 2008 in men who have had regular PSA analysis and, if possible, curatively intended treatment

of a newly diagnosed prostate cancer.

Downloads

Download data is not yet available.

Downloads

Published

2009-11-07

How to Cite

Fosså, S. D., & Høisæter, P. Å. (2009). Screening for prostatakreft i Norge. Norsk Epidemiologi, 11(2). https://doi.org/10.5324/nje.v11i2.549